Gilead Collaborates with Hookipa for HBV and HIV Therapies

Gilead Sciences GILDentered into a research collaboration and license agreement with Hookipa Biotech AG. Per the agreement, Gilead will own exclusive rights to Hookipa's TheraT and Vaxwave arenavirus vector-based immunization technologies for two major chronic infectious disease indications, hepatitis B virus (HBV) and human immunodeficiency virus (HIV).

While research work will be carried out by both, Hookipa will manufacture arenavirus-based vectors for clinical development by Gilead.